English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [2323]
News [5452]
Articles [134]
Editorials [4]
Conferences [158]
elearning [13]
Actionable targets in patients with cisplatin-resistant advanced germ cell...
Dr Aditya Bagrodia - Memorial Sloan Kettering New York, USA
Actionable targets in patients with cisplatin-resistant advanced germ cell tumours ( Dr Aditya Bagrodia - Memorial Sloan Kettering New York, USA )
7 Jan 2016
From genotype to molecular phenotype by proteomics
Dr Janne Lehtiö - Karolinska Institutet, Stockholm, Sweden
From genotype to molecular phenotype by proteomics ( Dr Janne Lehtiö - Karolinska Institutet, Stockholm, Sweden )
22 Dec 2015
The DNA damage response
Dr Helge Gad - Karolinska Institutet, Stockholm, Sweden
The DNA damage response ( Dr Helge Gad - Karolinska Institutet, Stockholm, Sweden )
22 Dec 2015
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy
Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015
Editor's choice for December 2015
Prof Gordon McVie - ecancer Editor
Editor's choice for December 2015 ( Prof Gordon McVie - ecancer Editor )
16 Dec 2015
Novel estrogen receptor-targeting agent represents ‘quantum leap’
Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA
Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )
15 Dec 2015
ASH 2015: Latest in CLL
Prof John Gribben, Prof Stephan Stilgenbauer, Dr Alessandra Tedeschi, Dr...
ASH 2015: Latest in CLL ( Prof John Gribben, Prof Stephan Stilgenbauer, Dr Alessandra Tedeschi, Dr Patrick Thornton )
7 Dec 2015
How can functional drug screening guide personalised cancer therapy?
Prof Jeff Tyner - Oregon Health & Science University, Portland, USA
How can functional drug screening guide personalised cancer therapy? ( Prof Jeff Tyner - Oregon Health & Science University, Portland, USA )
7 Dec 2015
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )
6 Dec 2015
First targeted therapy for multiple myeloma effective against hard-to-treat...
Dr Torben Plesner - Vejle Hospital, Vejle, Denmark
First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, Vejle, Denmark )
6 Dec 2015
First targeted therapy for genetically defined subset with acute myeloid...
Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA
First targeted therapy for genetically defined subset with acute myeloid leukaemia significantly improves survival ( Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA )
6 Dec 2015
Promising new strategy for treating children with acute lymphocytic leukaemia
Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA
Promising new strategy for treating children with acute lymphocytic leukaemia ( Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA )
5 Dec 2015
<1...136137138139140...194>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top